LETTERS

Which drugs to prescribe

 

Fam Pract Manag. 2006 Sep;13(8):16-24.

I enjoyed Dr. Philip Mohler’s article “New Drugs: How to Decide Which Ones to Prescribe” [June 2006]. However, it is missing two key pieces of advice. First, a new drug should not only be at least as effective as the older drug; its efficacy must also be measured using outcomes that actually matter to patients. All too often a drug is promoted because it provides a small benefit as measured by a disease-oriented outcome such as the effect on blood sugar or peak flow. What really matters is patient-oriented outcomes – the effect on morbidity, mortality, symptoms, cost and quality of life.

Second, Dr. Mohler includes colleagues as “unbiased” sources of information. Sadly, given the pervasive reach of pharmaceutical representatives and drug company advertising, they may not be unbiased. Also, the informal and often haphazard observations of an individual physician are fraught with unintentional bias and are no substitute for a careful, well-designed study.

Instead, I encourage readers to read the STEPS (Safety, Tolerability, Efficacy, Price, Simplicity) feature in American Family Physician, where every month we carefully and objectively review a new drug using just the criteria that Dr. Mohler proposes (go to https://www.aafp.org/afp/steps).

Author’s response:

Dr. Ebell’s thoughts are germane and appreciated. Unfortunately, surrogate outcomes and comparisons with only placebo are the (sub) standard mode of bringing drugs to market. As he posits, pharmaceutical marketing often highlights the statistical significance of outcomes that have little, if any, clinical utility.

Dr. Ebell’s comments regarding our physician colleagues’ lack of unbiased medication knowledge are on target. The pharmaceutical industry, with its glitzy pens, pads and pizza, remains the primary source of drug information for most physicians. Dr. Bob Goodman’s Web site, http://www.nofreelunch.org, documents the very powerful bias that physicians expose themselves to when they see drug reps and accept “free” sample medications.

WE WANT TO HEAR FROM YOU

Send your comments to fpmedit@aafp.org. Submission of a letter will be construed as granting AAFP permission to publish the letter in any of its publications in any form. We cannot respond to all letters we receive. Those chosen for publication will be edited for length and style.

 
 

Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact fpmserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


MOST RECENT ISSUE


Mar-Apr 2018

Access the latest issue
of FPM journal

Read the Issue


FPM E-Newsletter

Sign up to receive FPM's free, weekly e-newsletter, "Quick Tips & Insights."

Sign Up Now

SUPPLEMENTS

Helping Your Adolescent and Young Adult Patients Get the Preventive Care and Services They Need

The Adolescent Health Consortium Project has clarified clinical preventive service recommendations for adolescents and young adults.
 

Making Sense of MACRA: Navigate Changes to the Quality Payment Program in 2018

Here's how to succeed in the four performance categories of the Merit-based Incentive Payment System.